Research programme: skin disorder therapies - York Pharma

Drug Profile

Research programme: skin disorder therapies - York Pharma

Alternative Names: Skin protease inhibitors - York Pharma; VAMP inhibitors - York Pharma; Vitamin A metabolic pathway inhibitors - York Pharma; YP 003 programme - York Pharma; YP 004

Latest Information Update: 04 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator York Pharma
  • Class
  • Mechanism of Action Peptide hydrolase inhibitors; Retinoic acid metabolism modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atopic dermatitis; Malignant melanoma; Psoriasis

Most Recent Events

  • 24 Feb 2006 Preclinical trials in Malignant melanoma in United Kingdom (unspecified route)
  • 13 Sep 2005 Preclinical trials in Atopic dermatitis in United Kingdom (Topical)
  • 13 Sep 2005 Preclinical trials in Psoriasis in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top